# IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses

> **NIH ALLCDC U01** · SEATTLE CHILDREN'S HOSPITAL · 2024 · $1,234,285

## Abstract

We will conduct active, prospective inpatient, emergency department (ED) and asymptomatic
healthy control (HC) surveillance in children at SCH and affiliated clinics in the Seattle
metropolitan area. We will enroll subjects to describe the population-based burden of AGE and
ARI in King County and Snohomish County, WA and evaluate effectiveness of licensed
vaccines, such as influenza (Flu) and rotavirus (RV) vaccine (vx). We will assess the
epidemiology and natural history of pediatric respiratory and enteric viral diseases and assess
transmission dynamics for vx-preventable (RV, Flu) and potentially vx-preventable pathogens,
such as norovirus (NV), respiratory syncytial virus (RSV), and SARS-CoV-2. After obtaining
informed consent and assent, if applicable, in English or Spanish, we will interview families to
collect epidemiological and clinical information, vaccine history, and obtain study specimens
including respiratory and/or stool specimens, depending on clinical symptoms. Vaccination data
are recorded in our state vaccine database, which is very reliable and complete. During times of
COVID-19, novel methods of enrollment and capturing data may be utilized as per IRB-
approved protocols including verbal or online consent, telephone interviews to complete data
capture, and home specimen collection. Respiratory specimens and stool samples will be tested
for multiple respiratory and enteric pathogens using sensitive and specific molecular PCR tests
in laboratories using approved testing strategies that have been validated by proficiency testing.
With this information, in addition to publicly available state-wide data describing inpatient and
acute care visits in WA, we will obtain incidence rates of ED and inpatient visits and
characterization of illness for multiple viral pathogens, including those responsible for vx-
preventable disease and potentially vx-preventable disease, and others related to acute
respiratory and enteric diseases, such as rhinovirus, EVD-68, parainfluenza viruses,
adenoviruses, and human metapneumovirus. Additionally, we will continue ongoing surveillance
for Acute Flaccid Myelitis (AFM) throughout WA state. In collaboration with statewide AFM
expert and SCH neurologist, Dr. Catherine Otten and using WA DOH surveillance data we will
conduct active surveillance, establish incidence rates, and compare rates of AFM to current
circulation of respiratory and gastrointestinal infections. We will characterize the clinical
spectrum of AFM by evaluating clinical and laboratory data, MRI findings, therapeutic
interventions, and outcomes to inform early diagnosis, prognosis, prevention, and treatment.

## Key facts

- **NIH application ID:** 11046480
- **Project number:** 5U01IP001157-04
- **Recipient organization:** SEATTLE CHILDREN'S HOSPITAL
- **Principal Investigator:** JANET A ENGLUND
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2024
- **Award amount:** $1,234,285
- **Award type:** 5
- **Project period:** 2021-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11046480

## Citation

> US National Institutes of Health, RePORTER application 11046480, IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses (5U01IP001157-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11046480. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*